Virtual Library
Start Your Search
seungtaek Lim
Author of
-
+
P2.12 - Small Cell Lung Cancer/NET (ID 180)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.12-18 - Prevalence of DLL3 Expression and Its Prognostic Role in Extensive Stage Small Cell Lung Cancer (Now Available) (ID 1563)
10:15 - 18:15 | Author(s): seungtaek Lim
- Abstract
Background
Extensive stage small cell lung cancer (ES-SCLC) is a highly aggressive disease with a very poor prognosis, and there is a highly unmet need to develop new treatment strategy for them. Rovalpituzumab tesirine (Rova-T), an antibody drug conjugate directed against Delta-like protein 3 (DLL-3) has shown good efficacy in phase I and II clinical trials for the patients with ES-SCLC. We herein examined the prevalence of DLL3 protein expression and its prognostic role in ES-SCLC patients.
Method
Tumor samples of ES-SCLS were subjected to immune-histochemical staining for DLL3 (AbbVie Stemcentrx). Expression in at least 50% of cancer cells were defined as DLL3-high. The association of patients’ characteristics including gender, metastatic sites, and smoking history with DLL3 expression was analyzed by medical chart review. The correlation of DLL3 protein expression status with chemotherapy effect (PFS, OS and response rate) was analyzed. All the statistical analyses were performed by SPSS ver. 18.0 program.
Result
A total of 56 patients' sample were included in our analysis. The median age was 54 with a range of 44 to 86, and the majority of patients (N=49, 89.1%) are male. Above 90 percent of patients (N=50, 90.9%) received etoposide and cisplatin as chemotherapeutic regimen, and among the 47 patients evaluable for the response, the objective response rate (ORR) was 61.7% (1 complete response and 28 partial response). The median progression free survival (PFS) and overall survival (OS) was 175 days (95% confidence interval (CI), 130.4~220.0) and 250 days (95% CI, 184.0~316.0), respectively. DLL-3 high expression was observed in 91% of patients (N=50). It is not correlated with any of the patients’ characteristics and response to chemotherapy. In addition, there was no difference in PFS (242.0 vs. 165.0 days, p=0.900) or OS (160.0 vs. 250.0 days, p=0.975) according to DLL-3 expression.
Conclusion
Our study showed that DLL3 high expression was found in almost all tumor samples in ES-SCLC. Also, its expression was not correlated with the patients’ characteristics and prognosis of them. Further studies are warranted.
